JP2016530259A5 - - Google Patents

Download PDF

Info

Publication number
JP2016530259A5
JP2016530259A5 JP2016533909A JP2016533909A JP2016530259A5 JP 2016530259 A5 JP2016530259 A5 JP 2016530259A5 JP 2016533909 A JP2016533909 A JP 2016533909A JP 2016533909 A JP2016533909 A JP 2016533909A JP 2016530259 A5 JP2016530259 A5 JP 2016530259A5
Authority
JP
Japan
Prior art keywords
alkyl
compound according
compound
substituted
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016533909A
Other languages
English (en)
Japanese (ja)
Other versions
JP6495908B2 (ja
JP2016530259A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2014/067263 external-priority patent/WO2015022332A1/en
Publication of JP2016530259A publication Critical patent/JP2016530259A/ja
Publication of JP2016530259A5 publication Critical patent/JP2016530259A5/ja
Application granted granted Critical
Publication of JP6495908B2 publication Critical patent/JP6495908B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016533909A 2013-08-14 2014-08-12 ピリジノン Active JP6495908B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13180404.9 2013-08-14
EP13180404 2013-08-14
PCT/EP2014/067263 WO2015022332A1 (en) 2013-08-14 2014-08-12 Pyridinones

Publications (3)

Publication Number Publication Date
JP2016530259A JP2016530259A (ja) 2016-09-29
JP2016530259A5 true JP2016530259A5 (enExample) 2017-09-21
JP6495908B2 JP6495908B2 (ja) 2019-04-03

Family

ID=48951412

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016533909A Active JP6495908B2 (ja) 2013-08-14 2014-08-12 ピリジノン

Country Status (4)

Country Link
US (2) US20150051208A1 (enExample)
EP (1) EP3033335B1 (enExample)
JP (1) JP6495908B2 (enExample)
WO (1) WO2015022332A1 (enExample)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9266891B2 (en) 2012-11-16 2016-02-23 Boehringer Ingelheim International Gmbh Substituted [1,2,4]triazolo[4,3-A]pyrazines that are BRD4 inhibitors
JP2016507496A (ja) 2012-12-21 2016-03-10 ゼニス・エピジェネティクス・コーポレイションZenith Epigenetics Corp. ブロモドメイン阻害剤としての新規複素環式化合物
MX365864B (es) 2013-06-21 2019-06-18 Zenith Epigenetics Ltd Inhibidores de bromodominio biciclicos novedosos.
CA2915622C (en) 2013-06-21 2020-08-18 Zenith Epigenetics Corp. Novel substituted bicyclic compounds as bromodomain inhibitors
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
EA201690087A1 (ru) 2013-07-31 2016-08-31 Зенит Эпидженетикс Корп. Новые квиназолиноны как ингибиторы бромодомена
HRP20221389T1 (hr) 2013-10-18 2023-01-06 Celgene Quanticel Research, Inc. Inhibitori bromodomena
ES2750452T3 (es) * 2013-11-26 2020-03-25 Gilead Sciences Inc Derivados de quinolina como inhibidores del bromodominio
JP6469692B2 (ja) * 2013-12-09 2019-02-13 ユーシービー バイオファルマ エスピーアールエル Tnf活性のモジュレーターとしてのイミダゾピリジン誘導体
GB201321737D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
WO2016087936A1 (en) 2014-12-01 2016-06-09 Zenith Epigenetics Corp. Substituted pyridinones as bromodomain inhibitors
US10179125B2 (en) 2014-12-01 2019-01-15 Zenith Epigenetics Ltd. Substituted pyridines as bromodomain inhibitors
CN107207474B (zh) 2014-12-11 2021-05-07 恒翼生物医药科技(上海)有限公司 被取代的杂环作为溴结构域抑制剂
JP2017538721A (ja) 2014-12-17 2017-12-28 ゼニス・エピジェネティクス・リミテッドZenith Epigenetics Ltd. ブロモドメインの阻害剤
GB201503720D0 (en) * 2015-03-05 2015-04-22 Glaxosmithkline Ip No 2 Ltd Chemical compound
HK1249058A1 (zh) 2015-03-18 2018-10-26 Arvinas, Inc. 用於增强靶向蛋白质降解的化合物和方法
GB201504694D0 (en) 2015-03-19 2015-05-06 Glaxosmithkline Ip Dev Ltd Covalent conjugates
GB201504689D0 (en) * 2015-03-19 2015-05-06 Glaxosmithkline Ip Dev Ltd Chemical compounds
GB201506660D0 (en) * 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
CA2994969A1 (en) 2015-08-06 2017-02-09 Dana-Farber Cancer Institute, Inc. Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses
WO2017024408A1 (en) 2015-08-11 2017-02-16 Neomed Institute Aryl-substituted dihydroquinolinones, their preparation and their use as pharmaceuticals
WO2017024406A1 (en) 2015-08-11 2017-02-16 Neomed Institute N-substituted bicyclic lactams, their preparation and their use as pharmaceuticals
MX382832B (es) * 2015-08-12 2025-03-13 Epigenetix Inc Benzimidazoles sustituidos, su preparación y su uso como productos farmacéuticos.
EP3337476A4 (en) 2015-08-19 2019-09-04 Arvinas, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
US10501459B2 (en) 2015-10-21 2019-12-10 Neomed Institute Substituted imidazo[1,2-a]pyridines as bromodomain inhibitors
CN108602821B (zh) * 2015-12-14 2021-06-29 恒元生物医药科技(苏州)有限公司 1h-咪唑并[4,5-b]吡啶基bet溴结构域抑制剂
WO2017127930A1 (en) * 2016-01-28 2017-08-03 Neomed Institute Substituted [1,2,4]triazolo[4,3-a]pyridines, their preparation and their use as pharmaceuticals
ES3037659T3 (en) 2016-03-30 2025-10-03 Wisconsin Alumni Res Found Methods and compositions for modulating frataxin expression
CN109790143A (zh) 2016-05-10 2019-05-21 C4医药公司 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
WO2017197036A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
EP3454856B1 (en) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
GB201614939D0 (en) * 2016-09-02 2016-10-19 Glaxosmithkline Ip Dev Ltd Crystalline hydrate
GB201614940D0 (en) * 2016-09-02 2016-10-19 Glaxosmithkline Intellectual Property (No 2) Ltd Chemical compounds
WO2018106667A1 (en) 2016-12-05 2018-06-14 Microbiotix, Inc. Broad-spectrum inhibitors of filoviruses
KR102747905B1 (ko) 2017-01-31 2024-12-31 아비나스 오퍼레이션스, 인코포레이티드 세레블론 리간드 및 이를 포함하는 이작용성 화합물
WO2018148440A1 (en) 2017-02-08 2018-08-16 Dana-Farber Cancer Institute, Inc. Regulating chimeric antigen receptors
WO2018183679A1 (en) 2017-03-29 2018-10-04 Wisconsin Alumni Research Foundation Methods and compositions for modulating gene expression
EP3641762A4 (en) 2017-06-20 2021-03-10 C4 Therapeutics, Inc. N / O-LINKED DEGRONES AND DEGRONIMERS FOR PROTEIN DEGRADATION
CN109111437B (zh) * 2017-06-22 2022-03-04 中国科学院广州生物医药与健康研究院 一种苯并[d]异恶唑类化合物及其制备方法和应用
CN109280046B (zh) * 2017-07-21 2021-02-02 浙江海正药业股份有限公司 苯并咪唑类衍生物及其制备方法及其在医药上的用途
ES2909401T3 (es) * 2017-08-04 2022-05-06 Bristol Myers Squibb Co Compuestos de indol sustituidos útiles como inhibidores de TLR7/8/9
US20210038602A1 (en) * 2018-01-25 2021-02-11 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia
EP3743066A4 (en) 2018-01-26 2021-09-08 Yale University IMIDE-BASED PROTEOLYSIS MODULATORS AND RELATED METHODS OF USE
US10442799B1 (en) 2018-04-07 2019-10-15 Fuqiang Ruan Heterocyclic compounds and uses thereof
CN118480030A (zh) 2018-04-13 2024-08-13 阿尔维纳斯运营股份有限公司 小脑蛋白配体和包括其的双官能化合物
EP3897631A4 (en) 2018-12-20 2022-11-23 C4 Therapeutics, Inc. TARGETED PROTEIN BREAKDOWN
JP2022053557A (ja) * 2019-02-08 2022-04-06 マルホ株式会社 ピリドン誘導体
JP7603613B2 (ja) * 2019-04-24 2024-12-20 コンバージーン・リミテッド・ライアビリティ・カンパニー 小分子ブロモドメイン阻害剤およびそれらの使用
US20220378923A1 (en) 2019-09-30 2022-12-01 Kyowa Kirin Co., Ltd. Bet degrader
CN115175901B (zh) 2019-12-19 2024-03-22 阿尔维纳斯运营股份有限公司 用于雄激素受体的靶向降解的化合物和方法
WO2021175432A1 (en) 2020-03-04 2021-09-10 Boehringer Ingelheim International Gmbh Method for administration of an anti cancer agent
WO2024050016A1 (en) 2022-08-31 2024-03-07 Oerth Bio Llc Compositions and methods for targeted inhibition and degradation of proteins in an insect cell
WO2025049555A1 (en) 2023-08-31 2025-03-06 Oerth Bio Llc Compositions and methods for targeted inhibition and degradation of proteins in an insect cell

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004010207A1 (de) * 2004-03-02 2005-09-15 Aventis Pharma S.A. Neue 4-Benzimidazol-2-yl-pyridazin-3-on-Derivate
BRPI0709007A2 (pt) * 2006-03-09 2011-06-21 Pharmacopeia Inc inibidores de 8-heteroarilpurina mnk2 para tratamento de distúrbios metabólicos
AR063141A1 (es) * 2006-10-04 2008-12-30 Pharmacopeia Inc Derivados de 2- ( benzimidazolil ) purina 8- sustituida para inmunosupresion
WO2010107739A2 (en) * 2009-03-18 2010-09-23 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions of treating a flaviviridae family viral infection
EP2439197A1 (en) * 2010-10-07 2012-04-11 Santhera Pharmaceuticals (Schweiz) AG Substituted benzimidazole derivatives as melanocortin 4 receptor antagonists

Similar Documents

Publication Publication Date Title
JP2016530259A5 (enExample)
JP2016515561A5 (enExample)
JP2016540742A5 (enExample)
JP2019524883A5 (enExample)
JP2017517565A5 (enExample)
JP2014521688A5 (enExample)
JP2014511892A5 (enExample)
JP2015501833A5 (enExample)
JP2012532136A5 (enExample)
JP2014511891A5 (enExample)
JP2015504081A5 (enExample)
JP2016515560A5 (enExample)
JP2013537203A5 (enExample)
JP2018524390A5 (enExample)
JP2015078230A5 (enExample)
JP2019526596A5 (enExample)
JP2015537020A5 (enExample)
JP2015509535A5 (enExample)
JP2018537413A5 (ja) 化合物、医薬的に許容される塩又はその立体異性体及び医薬組成物
JP2013508279A5 (enExample)
JP2015516427A5 (enExample)
JP2019500387A5 (enExample)
JP2016503797A5 (enExample)
RU2016134751A (ru) Соединения
JP2016531126A5 (enExample)